MGX Metagenomi Inc.: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The market dynamics for Metagenomi, Inc. (MGX) reflected in the EV/EBITDA multiple stand at 0.00. The asset demonstrates high recession resilience, as the development of CRISPR therapy relies on scientific breakthroughs rather than GDP. Metagenomi, Inc. (MGX) creates precision therapy tools by leveraging metagenomic data arrays. This innovative gene-editing segment remains independent of economic cycles and macroeconomic conditions.
Analytical breakdowns for Metagenomi, Inc.
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
Total Debt to Capital Metagenomi, Inc.|MGX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Metagenomi, Inc|MGX - Aggregate Debt Obligations|Debts to Book Capitalization Metagenomi, Inc|MGX - Long-Term Debt Volume|Company Short-Term Debt Metagenomi|Quick Ratio metagenomi.co
- business earnings and investment ratios data:
MGX - Net Income|Future Profit Metagenomi, Inc.|MGX - Business Payback Period|Future Price to Earnings Metagenomi Inc.|MGX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Metagenomi, Inc.|MGX - Operating profit before depreciation charges|Net earnings per share for the last 12 months Metagenomi|MGX - Earnings per share for the last 12 months|Quarterly EPS earnings growth metagenomi.co|MGX - Earnings per share growth this year|Net earnings per share growth forecast for next year Metagenomi, Inc.
- revenue and sales details:
Summary company analysis:metagenomi.co MGX
The integration of AI libraries and gene editing within the Metagenomi, Inc. (MGX) ecosystem requires significant capital expenditures, making the valuation of the business relative to its operating profit critically important. By analyzing the current EV/EBITDA multiple, an investor compares the total enterprise value, accounting for debt and cash, against the company's ability to generate cash flow to determine the asset's resilience to macroeconomic shocks.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempus AI TEM|qiagen.com (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Repligen (RGEN)|RNA (Avidity) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics AG - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GeneDx Holdings|Enterprise Value to Operating Income Before Depreciation RARE (Ultragenyx)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics (BEAM)|Enterprise Value to Operating Income Before Depreciation Ratio SRPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience Corp TWST|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics, Inc. (TXG)|Intellia Therapeutics - EV/EBITDA Multiple|STOK - EV/EBITDA Multiple|BLFS (biolifesolutions.com) - Enterprise Value to EBITDA Ratio|WVE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio MAZE|Sionna Pharma - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PRME|TSHA (Taysha Gene Therapies) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization uniQure QURE|MGTX: Enterprise Value to Operating Income Before Depreciation|REGENXBIO Inc - EV/EBITDA Multiple|Company Value to EBITDA Solid Corp|Ocugen (OCGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Pacific Biosciences|Enterprise Value to EBITDA Ratio BNTC|Enterprise Value to EBITDA Ratio Design Therapeutics Inc (DSGN)|EV/EBITDA Multiple RCKT|EV/EBITDA Multiple 4D Molecular Therapeutics, Inc. (FDMT)|lexeotx.com - Enterprise Value to EBITDA Ratio|KRRO: Enterprise Value to Operating Income Before Depreciation|Editas Corp - EV/EBITDA Multiple|SLN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRQR (ProQR) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation CDXS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization sangamo.com|Enterprise Value to Operating Income Before Depreciation NAUT (Nautilus Biotechnology)|EV/EBITDA Multiple DTIL|Generation Bio - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio Inc.)|Business Value to Operating Income Before Depreciation XCUR|Imunon Inc - EV/EBITDA Multiple|PHIO (phiopharma.com) - Enterprise Value to Operating Income Before Depreciation|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Corp|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple ImmunoPrecise Antibodies Ltd. (IPA)|EV/EBITDA Multiple OMGA (omegatherapeutics.com)|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals, Inc)|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology, Inc
